Spinraza

(nusinersen)
Spinraza 12 MG in 5 ML Injection
NO BOXED WARNING

Dosage & administration

SPINRAZA is administered intrathecally

Dosing Information

Important Preparation and Administration Instructions


Laboratory Testing and Monitoring to Assess Safety


drug label

Spinraza prescribing information

prior authorization

Spinraza prior authorization resources

Most recent Spinraza prior authorization forms

View By Payer
Verified: Feb 07, 2024Kaiser Foundation Health Plan - Chronic High-Dose Opioid Therapy Prior Authorization Form Washington
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Medical Injectable Specialty Drug Prior Authorization Form
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Outpatient Chemotherapy Prior Authorization Form (Medical Benefit)
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Specialty Drug Prior Authorization Form
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Non-Formulary Drug Coverage Prior Authorization Form

Most recent state uniform prior authorization forms

Verified: Jan 28, 2024Oregon - Uniform Prior Authorization Form
Verified: Jan 28, 2024Colorado - Uniform Prior Authorization Form
Verified: Jan 28, 2024Michigan - Uniform Prior Authorization Form
Verified: Jan 28, 2024Hawaii - Uniform Prior Authorization Form
Verified: Jan 28, 2024Minnesota - Uniform Prior Authorization Form
Verified: Jan 28, 2024New Hampshire - Uniform Prior Authorization Form
Verified: Jan 28, 2024New Mexico - Uniform Prior Authorization Form
Verified: Jan 28, 2024Texas - Uniform Prior Authorization Form
Verified: Jan 28, 2024Louisiana - Uniform Prior Authorization Form
Verified: Jan 28, 2024Arizona - Uniform Prior Authorization Form
Verified: Jan 28, 2024Indiana - Uniform Prior Authorization Form
Verified: Jan 28, 2024Illinois - Uniform Prior Authorization Form
Complete Letter of Medical Necessity
Requesting Medical Exceptions and Appealing Denials Guide
Prior Authorization Submissions Guide
Learn More

Benefits investigation

Spinraza Start Form
Spinraza Start Form - Spanish
Spinraza Start Form - Online
Learn More

pharmacy

Spinraza preferred pharmacy

Pharmacy List

Financial Assistance

Financial Assistance Programs

Spinraza retails for $29,044 per dose without insurance or financial assistance.Depending on your patient's insurance situation and other eligibility criteria, they may be able to get Spinraza for significantly less. Review the program information below to determine what program can offer your patient the most benefits.
CoPay Card Program$0 Co Pay
Available for
commercial
Program Details
  • $29044 for Solution
Forms
Spinraza Start Form
Spinraza Start Form - Spanish
Spinraza Start Form - Online
Enroll in Patient Savings Program

PubMed™ | Spinraza

Spinraza PubMed™ News

patient education

Spinraza patient education

To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link

Patient toolkit

Spinraza Start Form - Online
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure: Adults
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure: Pediatrics
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
About Spinraza
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Side Effects
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Receiving Spinraza
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Stories: Adults
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Stories: Children
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Learn More

people also ask

Spinraza FAQs

8.1 PregnancyThere is insufficient data regarding the developmental risk of using SPINRAZA in pregnant women. Animal studies showed developmental toxicity (long-term neurobehavioral impairment) at all tested doses. The background risk of birth defects and miscarriage in the indicated population is unknown.
8.2 LactationThere is no data on nusinersen presence in human milk or its effects on breastfed infants. Nusinersen was found in the milk of lactating mice when given by injection. The decision to breastfeed should consider both the benefits of breastfeeding and the mother's clinical need for SPINRAZA, weighing any potential adverse effects.
8.4 Pediatric UseSPINRAZA's safety and effectiveness have been established in pediatric patients from newborn to 17 years old based on clinical studies.
8.5 Geriatric UseClinical studies of SPINRAZA did not sufficiently include subjects aged 65 and over to determine potential differences in response compared to younger subjects.
FAQ Data Source